Twinbeech Capital LP Acquires 3,335 Shares of Amgen Inc. (NASDAQ:AMGN)

Twinbeech Capital LP lifted its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 178.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,204 shares of the medical research company's stock after buying an additional 3,335 shares during the period. Twinbeech Capital LP's holdings in Amgen were worth $1,356,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in AMGN. Capital World Investors increased its position in shares of Amgen by 1,292.0% in the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock valued at $1,693,042,000 after buying an additional 6,029,058 shares in the last quarter. Norges Bank bought a new stake in shares of Amgen in the 4th quarter valued at $1,541,991,000. Capital International Investors increased its position in shares of Amgen by 40.1% in the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock valued at $3,182,843,000 after buying an additional 3,495,503 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Amgen by 25.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock worth $3,441,909,000 after purchasing an additional 2,672,975 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in Amgen in the 4th quarter worth $401,913,000. Institutional investors own 76.50% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on AMGN shares. Citigroup reaffirmed a "neutral" rating on shares of Amgen in a research note on Wednesday, February 5th. UBS Group reaffirmed a "neutral" rating and issued a $315.00 target price (down from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Johnson Rice set a $294.00 target price on shares of Amgen in a research note on Wednesday, March 5th. Piper Sandler reduced their target price on shares of Amgen from $329.00 to $328.00 and set an "overweight" rating for the company in a research note on Friday, May 16th. Finally, Cantor Fitzgerald started coverage on shares of Amgen in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $305.00 target price for the company. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $309.22.

Amgen Stock Performance

NASDAQ:AMGN traded down $0.24 during mid-day trading on Friday, hitting $271.66. The stock had a trading volume of 2,531,997 shares, compared to its average volume of 2,795,937. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The stock has a market cap of $146.07 billion, a price-to-earnings ratio of 35.98, a PEG ratio of 2.63 and a beta of 0.51. The company's 50 day simple moving average is $286.82 and its 200 day simple moving average is $286.72. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.72. The business had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Amgen's revenue was up 9.4% on a year-over-year basis. During the same period last year, the business posted $3.96 EPS. On average, equities research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.50%. Amgen's dividend payout ratio is currently 86.86%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.